Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia is capped, with peak sales estimates around $500M, insufficient alone for profitability; SCD approval remains a major potential catalyst. AGIO maintains a strong cash position of $1.3B versus $101M in liabilities, providing ample runway for commercialization and further development.
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
